Clinical Trials in Ohio

Showing 20341-20360 of 20,938 trials

Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML)

NCT00064584

This is the first study of the drug CT53518 when given to humans. The purpose of this study is to determine the highest dose of CT53518 that can safely be given to patients with Acute Myelogenous Leukemia (AML) and to identify the side effects associated with taking the drug. The study will evaluate how CT53518 is absorbed, broken down, and eliminated by the body. Additionally, the study will evaluate the effects of the drug on a specific type of cell in bone marrow and blood, known as a blast.

Acute Myelogenous LeukemiaMyelodysplastic Syndrome

Millennium Pharmaceuticals, Inc.60 participantsStarted May 2002

Los Angeles, California, United States • Boston, Massachusetts, United States • New York, New York, United States +2 more locations

COMPLETEDPhase 232 miles

A Long-Term Safety Study of IDEA-033 in Comparison to Oral Naproxen for the Treatment of Osteoarthritis of the Knee

NCT00265304

The purpose of this study is to evaluate the long-term safety of IDEA-033 (an anti-inflammatory pain-relieving drug applied to the skin) in comparison to naproxen (an anti-inflammatory pain-relieving drug taken by mouth) for the treatment of osteoarthritis of both knees.

Osteoarthritis, Knee

IDEA AG550 participantsStarted Jul 2005

Birmingham, Alabama, United States • Montgomery, Alabama, United States • Montgomery, Alabama, United States +90 more locations

Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML)

A Long-Term Safety Study of IDEA-033 in Comparison to Oral Naproxen for the Treatment of Osteoarthritis of the Knee

Find Trials by Condition in Ohio

ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere

Efficacy & Safety of Quetiapine Fumarate (SEROQUEL) & Placebo in the Treatment of Acutely Ill Patients With Schizophrenia

Safety and Efficacy Maintenance Study of Quetiapine SR to Treat GAD Patients.

Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder

Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS)

Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Generalized Anxiety Disorder

Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in Combination With an Antidepressant in the Treatment of Major Depressive Disorders

Phase 3 /Seroquel SR Acute Mania Monotherapy - US

A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C

Lofexidine for Inpatient Opiate Detox

Genetics of Progressive Multifocal Leukoencephalopathy and Acquired Immunodeficiency Syndrome

Safety, Tolerability, Immunological and Clinical Efficacy of Multiple Subcutaneous Doses of DiaPep277 in Latent Autoimmune Diabetes in Adults (LADA)

An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD)

Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD

Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment

Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting Criteria for Chronic Constipation

Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis in Myocardial Infarction

A Study of SR58611A in the Prevention of Depression Relapse in Patients With Major Depressive Disorder